A cross-section, observational, drug utilization study to assess productive cough symptom control in Br. asthma and phenotypes (ASTHMA*Cough study)

Glenmark Pharmaceuticals Ltd0 个研究点目标入组 110 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Adults with bronchospastic respiratory conditions or bronchial asthma requiring outpatient therapy with bronchodilatory or mucolytic cough formulations.

•Patients with < 1 follow up visit to be excluded from this concurrent analyses
•Patients with hospitalization in the last four weeks for Uncontrolled asthma or requiring inhaled SABA of >=6 dosages in a day for the last week
•Patients who have been hospitalized and received antimicrobial therapy within the last 24 hours
•Patients at high risk for infection with 6Ps; pneumonia, pulmonary embolism, pneumothorax, pleural effusion, pulmonary oedema [heart failure] and paroxysmal atrial tachycardia(arrhythmias)

发起方

Glenmark Pharmaceuticals Ltd